

Although the results are interesting, it is a pity that the logic of using knock-in approaches was not continued with the *APP* gene. Using a humanized knock-in *APP* sequence would have mimicked the human situation even better. Nevertheless, the results strongly support the pathogenic role of A $\beta$ 43 *in vivo*: the substantial rise in soluble and insoluble A $\beta$ 43 apparently caused memory impairment, even in young mice. Notably, relative and absolute levels of A $\beta$ 42 and A $\beta$ 40 were unchanged in the animals. Thus, the authors concluded that the A $\beta$ 43 species might trigger an early Alzheimer's disease-related memory loss in these animals. Finally, Saito *et al.*<sup>3</sup> demonstrate a correlation between the steady-state levels of A $\beta$ 43 generated by cells expressing different familial presenilin 1 mutant proteins and age of onset in people with the corresponding familial Alzheimer's disease. A similar correlation was found before with A $\beta$ 42 (ref. 9), but the new result strengthens the hypothesis that A $\beta$ 43 contributes to Alzheimer's disease.

Although this suggestion logically follows the experimental results, one must be cautious regarding extrapolation to human Alzheimer's disease for several reasons. First, despite the confirmed presence of A $\beta$ 43 in amyloid plaques of human sporadic Alzheimer's disease and familial inherited Alzheimer's disease associated with *APP* and presenilin mutations<sup>10</sup>, its concentration is several-fold less than that of A $\beta$ 42 (ref. 11), a predominant species in plaques. Second, A $\beta$ 43, let alone its longer precursors, is highly hydrophobic and does not easily leave the cell membrane environment<sup>11</sup>. Thus, the role of A $\beta$ 43 might still be indirect, driving neurotoxicity mostly by acting as a seed that interacts with the more abundant A $\beta$  species. The role of the cell membrane and lipids in

this process also remains poorly understood<sup>12</sup>. Finally, the amyloidogenicity of A $\beta$ 43 and A $\beta$ 42 has not been extensively compared<sup>10,13</sup>. Other questions raised by work of Saito *et al.*<sup>3</sup> are the extent to which A $\beta$ 43 could contribute to the formation of Alzheimer's disease-relevant toxic A $\beta$  conformers, such as human brain-derived dimers<sup>5</sup> or amylospheroids<sup>6</sup>, and whether A $\beta$ 43 species may drive both sporadic and familial Alzheimer's disease.

Mechanistically, the question remains how exactly the clinical mutations affect the length of the A $\beta$  peptides. This will need careful measurements of kinetic parameters of the  $\gamma$ -secretase enzyme and determination of the effect of the mutations on those properties. Such work is only possible with *in vitro* assays. However, the authors did make a series of intriguing observations in their *in vivo* experiments. For instance, A $\beta$ 43 accumulation was associated with A $\beta$ 46 accumulation in homozygous presenilin 1 R278I fibroblasts, corroborating a previously proposed model of tripeptide-wise *APP* cleavage<sup>11,14</sup> (Fig. 1). In addition, Saito *et al.*<sup>3</sup> investigated an interesting allelic series of fibroblast mutant cell lines. From those experiments, it emerged that the production of A $\beta$ 43 is lower in heterozygous cells that contain one disease allele and one wild-type allele than in cells that contain one disease allele and one knock-out allele. The authors suggest that intermediary cleavage products of the consecutive A $\beta$  processing, such as A $\beta$ 43, can be transferred to the wild-type allele for further processing (Fig. 1). In the absence of the wild-type allele, processing stops at the A $\beta$ 43 form, which is therefore released more abundantly. However, further support for this idea can only come from detailed *in vitro* kinetic studies.

In conclusion, this study points to the importance of qualitative changes in the A $\beta$  peptide spectrum, as opposed to quantitative changes in total A $\beta$  peptide release, for our understanding of Alzheimer's disease and the role of A $\beta$  peptides in neurodegeneration. The apparent paradox that loss of function of  $\gamma$ -secretase resulting from clinical mutations<sup>15</sup> can lead to decreased total A $\beta$  peptide generation while still causing amyloid plaques and Alzheimer's disease can only be resolved if it is accepted that qualitative changes in the A $\beta$  peptides are more important than quantitative changes. This has obvious implications for drug development.

#### COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details accompany the full-text HTML version of the paper at [www.nature.com/natureneuroscience/](http://www.nature.com/natureneuroscience/).

1. Hardy, J. & Selkoe, D.J. *Science* **297**, 353–356 (2002).
2. Hardy, J. *J. Neurochem.* **110**, 1129–1134 (2009).
3. Saito, T. *et al. Nat. Neurosci.* **14**, 1023–1032 (2011).
4. De Strooper, B., Vassar, R. & Golde, T. *Nat. Rev. Neurosci.* **6**, 99–107 (2010).
5. Jin, M. *et al. Proc. Natl. Acad. Sci. USA* **108**, 5819–5824 (2011).
6. Noguchi, A. *et al. J. Biol. Chem.* **284**, 32895–32905 (2009).
7. Bentahir, M. *et al. J. Neurochem.* **96**, 732–742 (2006).
8. De Strooper, B. *et al. EMBO J.* **14**, 4932–4938 (1995).
9. Kumar-Singh, S. *et al. Hum. Mutat.* **27**, 686–695 (2006).
10. Welander, H. *et al. J. Neurochem.* **110**, 697–706 (2009).
11. Qi-Takahara, Y. *et al. J. Neurosci.* **25**, 436–445 (2005).
12. Martins, I.C. *et al. EMBO J.* **27**, 224–233 (2008).
13. Jarrett, J.T., Berger, E.P. & Lansbury, P.T. Jr. *Biochemistry* **32**, 4693–4697 (1993).
14. Takami, M. *et al. J. Neurosci.* **29**, 13042–13052 (2009).
15. De Strooper, B. *EMBO Rep.* **8**, 141–146 (2007).

## Reward and autoreceptors

Both natural rewards and addictive drugs increase extracellular dopamine (DA) in the striatum. Although studies have found that DA receptors are involved in addiction, the results are conflicting. Susceptibility to drug addiction is correlated with reduced availability of striatal D<sub>2</sub> receptors, yet D<sub>2</sub> receptor knockout mice show reduced responses to drugs of abuse. These contradictory results may arise because there are two populations of D<sub>2</sub> receptors. Most D<sub>2</sub> receptors are postsynaptic, responding to DA release from striatal dopaminergic neurons. However, D<sub>2</sub> receptors are also expressed presynaptically on DA-releasing neurons (autoreceptors), which exert negative feedback. Previous genetic and pharmacological studies have not been able to differentiate between these two populations of D<sub>2</sub> receptors. On page 1033, Bello and colleagues dissect the selective role of D<sub>2</sub> autoreceptors and find that deleting D<sub>2</sub> autoreceptors increases DA synthesis and release, resulting in increased sensitivity to cocaine.

The authors created mice lacking D<sub>2</sub> receptors only in DA-releasing neurons (autoDrd2KO mice). Striatal dopaminergic neurons in autoDrd2KO mice did not show inhibitory currents in response to D<sub>2</sub> agonists. This lack of negative feedback was accompanied by increased DA synthesis and release. AutoDrd2KO mice were hyperactive, and hypersensitive to cocaine. They exhibited increased cocaine-seeking in a conditioned place preference procedure and worked harder for a food reward in an operant conditioning procedure, suggesting that the role of D<sub>2</sub> autoreceptors extends to natural rewards.



Brigitta Gundersen